STUDresearch · Peptide
DSIP
Also known as
Delta Sleep-Inducing Peptide · Delta-sleep-inducing peptide · DSIP nonapeptide · Emideltide (compounding / INN-style name) · Deltaran (Russian DSIP-containing preparation; not identical pure research vial) · Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu · WAGGDASGE (sequence shorthand)
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Systemic
SubQ / Nasal
Sleep peptides
Systemic — whole-system sleep/stress neuromodulation and neuroendocrine talk; not local tissue repair.
What people say
DSIP is a sleep-related peptide people discuss for deeper rest, fewer wake-ups and feeling better the next morning. Community experiences range from noticeably better sleep to no change.
Doses people talk about
Historical IV studies used weight-based amounts and cannot validate the same mass by another route.
How it may feel
Reports include sleepiness, vivid dreams and a more rested morning. Others describe grogginess, disrupted sleep or nothing noticeable; wearable scores are not proof of a peptide effect.
SubQ injection
Common chart range100–300 mcg subcutaneous per dose
Vendor/forum charts discuss nightly short runs and intermittent nights; neither is an established safe or effective schedule.
Nasal spray / solution
Separate community band~100–500 mcg per session
Community discussion with uncertain absorption and device effects. This is not a conversion from SubQ or historical IV amounts.
SubQ injection
Higher anecdotal reports400–500 mcg subcutaneous per dose
Some logs describe this range after little effect at lower amounts; the reports do not establish that increasing improves sleep or safety.
Half-life & effect duration
- Half-life in the body
- IV · dogsAbout 4 minutes
- Community / secondary estimatesAbout 7–8 minutes or 30–45 minutes
- Brain-tissue breakdown testAbout 15 minutes
- Felt duration people report
- One sleep accountDozing after about 30 minutes; refreshed the next morning
- Other early reportsSleep pressure within about 30–60 minutes, vivid dreams, or no benefit
Cycles people discuss
Community patterns include short one-to-four-week blocks, intermittent nights and occasional use without a formal cycle. Claims that breaks prevent tolerance are not established by those schedules.
Timing
Evening use near intended sleep is the main discussion pattern. Comparing a whole night's sleep and the next morning is different from tracking how long the peptide stays in blood.
Stacks
Sleep hygiene base first: Dark/cool room, fixed schedule, caffeine cutoffs, alcohol limits — often credited as much as the peptide.
Access talk
2026 community shrug: Peptide-twitter / forum reaction to the no-vote was often “not surprised” / non-responder talk, not a supply panic. RUO vials and clinic nasal/injectable SKUs remain the actual buy talk.
Watch for
Sedative / alcohol combinations: Theoretical additive CNS depression with benzos, Z-drugs, barbiturates, or heavy alcohol — uncharacterized and widely discouraged in community safety notes.
Tap a line for the full notes and source context.
Timing context & sources
Half-life in the body
A human half-life is not established by the sources checked. The measured four-minute figure comes from IV DSIP in dogs.
The often-repeated 15 minutes concerns breakdown in brain slices and homogenates, not clearance from a person.
Kato's original abstract reports 4.0 ± 0.7 minutes in four dogs using an enzyme immunoassay, with different monkey/rat figures. Schoenenberger's original abstract describes the separate laboratory endpoint. Neither establishes modern human subcutaneous or nasal clearance; full papers were not reviewed. FDA’s detailed PK review also separates human-serum degradation in vitro from living-human clearance; its eight-minute shorthand is not a validated SC measurement.
- Kato et al. (1984): DSIP clearance in dogs (opens in a new tab)Original abstract: enzyme immunoassay, four anesthetized dogs, IV administration, mean half-life 4.0 ± 0.7 minutes; separate monkey and rat results.Animal experiment and abstract only. Immunoreactivity is not a human subcutaneous or nasal PK measurement.
- Schoenenberger (1984): DSIP characterization and degradation (opens in a new tab)Original abstract, paragraph on proteolytic tryptophan split-off by brain slices/homogenates: 15 minutes. Read through the public Europe PMC core-record API.The supplied abstract is truncated at 400 words; relevant degradation paragraph is present. Laboratory endpoint, not a human plasma half-life; full review not read.
- DSIP / Emideltide: route and historical-dose review (opens in a new tab)FDA Emideltide briefing: printed pages 21–22 marketed products; 25,27–28 historical human IV studies and 25 nmol/kg conversion; 44 animal IV/in-vitro serum endpoints; 49 eight-minute shorthand. Actual independent text inspection September 6.FDA literature review, not a new human clearance study. Printed page 49 shorthand does not establish human SC PK; marketed products are not historical IV study preparations.
Felt duration people report
One user describes dozing after about half an hour and waking refreshed; others report no benefit. A reliable effect duration is not established.
Falling asleep, staying asleep and feeling rested the next morning are different observations—not a measured half-life.
tballz's dated single-person report does not specify route. BeonBurps and ChiubiPeanut report no DSIP benefit in a mixed-peptide discussion. Their comments do not establish response rates. The neighboring eight-hour account explicitly concerns phospho-DSIP and is excluded.
- DSIP experience: sleep onset and next-morning feeling (opens in a new tab)tballz, post 5, August 28, 2014: dozing after about half an hour and feeling refreshed on waking.Single dated report, route/product identity unverified. Adjacent post 4 is phospho-DSIP and is not adopted as plain-DSIP evidence. No administration advice adopted.
- Community contrast: DSIP nonresponse (opens in a new tab)ChiubiPeanut reports DSIP did nothing; BeonBurps reports no benefit and a possible headache. Actual comments read, not adjacent Epitalon/modified-peptide experiences.Mixed-peptide discussion, self-selected reports, unspecified DSIP routes/duration; not prevalence or comparative effectiveness.
What people say
- Deeper sleep feel: Subjectively deeper rest and better morning recovery are the #1 community claim; many track with Oura/Whoop/Apple deep-sleep minutes. forum
- Fewer night wake-ups: Subset reports fewer middle-of-night awakenings; non-responders and paradoxical worse sleep are both common in threads. anecdote
- Jet lag / shift windows: Short-run tool to deepen whatever sleep opportunity exists at destination or post-shift — almost entirely anecdotal. forum
- Vivid / memorable dreams: Very high talk volume — “Inception,” multi-layer, and occasional lucid dreams; some chase this, others find it sleep-fragmenting. forum
- Next-day readiness without pill hangover: Responders contrast vs melatonin grogginess or Z-drug fog; not universal (higher mcg logs report morning fog). forum
- Stack confounds: Multi-peptide nights (Ipa/CJC/MK-677/Selank/BPC) make single-agent credit unreliable. forum
- Faster sleep onset: Early human work and user logs often cite shorter time-to-sleep when timed before bed. trial
- Sleep efficiency / fewer arousals: Schneider-Helmert-era insomnia work and a later double-blind chronic-insomnia study reported higher sleep efficiency and shorter latency vs placebo — effects described as statistically present but sometimes “little clinical significance” in critical reads. trial
- Slow-wave / delta architecture: Animal EEG delta promotion is the origin story; some human PSG reports increased stage 2 / NREM totals more than pure stage 3–4 in certain designs — bro content often overstates pure “delta expansion.” trial
- Stress-related / high-cortisol sleep: Framed as evening calm and HPA wind-down more than hard sedation; small human endocrine notes on cortisol/ACTH pattern modulation are cited. trial
- Historical withdrawal support: 1980s open clinical series (Dick et al. and related) gave IV DSIP during alcohol or opiate withdrawal with high rates of rapid symptom improvement in uncontrolled designs — not modern outpatient community primary use and not a detox protocol. trial
- Analgesia / pain sleep (preclinical & sparse human): Central antinociception in rodents; limited chronic-pain human exploration where better sleep was secondary. animal
- Animal sleep models: Rabbit/cat/rat slow-wave and sleep-pattern endpoints with variable replication; stronger effects often claimed for more stable analogues. animal
- Stress-limiting / antioxidant narratives: Rodent stress and mitochondrial/oxidative-phosphorylation papers circulate in stack writeups — far from human sleep RCTs. animal
- What it is not proven for: No large modern Phase III insomnia program; long-term safety, dependence, and subq bioavailability vs historical IV doses remain poorly characterized. trial
Doses people talk about
SubQ injection · community discussion
- Community subq common band: ~100–300 mcg per dose is the dominant chart range across vendor/clinic and forum writeups. forum
- “Standard” chart dose: ~200 mcg subq ~30–60 min before bed is frequently labeled the middle/most-used protocol in peptide-blog charts. forum
- Enhanced chart dose: ~300 mcg subq when lower bands felt subtle — still inside common charts. forum
- Higher anecdotal logs: ~400–500 mcg (and occasional ~750 mcg “too real dreams” reverse) appear in Reddit/self-experiment posts when 100–300 felt underwhelming — not trial-validated. anecdote
- Broad community envelope: Vendor/calculator discussion sometimes spans ~100–500 mcg or even up to ~1000 mcg entered doses; 80%-style aggregates of calculator submissions cluster widely inside the 100–1000 mcg window with lower modes more common. forum
- 2026 “start too low” vs “less is more”: Charts still open at 100–300 mcg. Some 2026 reviewers skip that and start ~500 mcg because 100–300 “felt like nothing”; other r/Peptides comments still say start under 300 and that 100–150 knocks them out. forum
- 400–500 mcg logs: r/sleep and r/BodyHackGuide 2026 posts treat 400–500 mcg SubQ as the bump after 300 mcg underwhelmed — still inside the older 100–1000 mcg envelope, not a new standard. forum
- 750 mcg “too real” then back down: A May 2026 lucid-dream writeup ran 500 mcg nightly, tried 750 mcg once, called the dream too real, and returned to 500. Anecdote, not a ceiling study. anecdote
- 1 mg minority: Feb 2026 r/Peptides still has 1 mg (~1000 mcg) 3 hours before bed, or 1 mg every other day stacked with CJC/ipa. Loud disagreement vs “less is more.” forum
Nasal spray / solution
- Nasal community band: ~100–500 mcg/session discussed; often assumed less predictable absorption than subq; congestion and spray technique confounds. forum
Historical IV research · separate units
- Identity / units first: Historical human trial amounts here are nmol/kg IV; modern gray-market talk is absolute mcg subq — do not assume 1:1 route or bioavailability equivalence. trial
- Historical human IV anchor: ~25 nmol/kg body weight as slow IV infusion is the classic Schneider-Helmert / related insomnia protocol dose (single or multi-night). trial
- Mass conversion of that IV band: At MW ~849–850 Da, 25 nmol/kg ≈ ~21.2–21.4 mcg/kg → roughly ~1.5 mg total for a ~70 kg adult (~1.5 mg range is trial-route math, not a community subq “standard”). trial
- Withdrawal-era IV band: Open clinical / patent-adjacent work discussed IV infusions on the order of ~0.0214 mg/kg (~21.4 mcg/kg) per infusion, sometimes multiple infusions per day in inpatient withdrawal settings — different context than sleep optimization. trial
- Historical dose correction: The cited 25–30 nmol/kg sleep studies used IV administration, not intranasal dosing. At free-base MW 848.814, 25 nmol/kg is about 21.2 mcg/kg, approximately 1.49 mg for 70 kg. The former low-to-mid-hundreds-of-micrograms description was incorrect. This does not establish an intranasal or subcutaneous equivalent. trial
- Not interchangeable: Subq mcg charts are not validated equivalents of historical IV nmol/kg exposure; assuming IV-equivalent CNS exposure from the same mcg mass is a common bro error. trial
Additional dose and source context
- Framing: Community-reported and historical trial discussion ranges only — not medical advice, not prescriptions, not FDA-labeled dosing. forum
- Timing — primary: ~30–60 minutes before intended lights-out is the dominant community instruction. forum
- Timing — tighter research echo: Some evidence-focused writeups prefer ~20–30 minutes pre-sleep because of rapid plasma clearance. trial
- Timing — longer window minority: Some charts allow ~1–3 hours pre-bed; inject-too-early complaints (cascade “missed”) also appear. forum
- Frequency — nightly short run: Nightly for ~2–4 weeks then off is a common template. forum
- Frequency — 5 on / 2 off: Clinic-style peptide schedules sometimes apply 5 nights on / 2 off during a block. forum
- Frequency — 2–3 nights/week: Many “clinical observation” notes prefer intermittent use to “preserve response” rather than every night — not PK-proven. forum
- Frequency — as-needed only: Single bad nights, travel arrival nights, or high-stress weeks without a formal cycle. forum
- Sublingual / oral talk: Occasional marketed tablets/drops; oral peptide survival expected poor; verification weak. forum
- Uncertainty: Labeled mcg ≠ verified purity/identity; gray-market COA quality varies; no consensus MTD or dose-response curve in modern RCTs. forum
- 5 on / 2 off still copied: One 2026 r/sleep comment kept five nights on / two off, with long 90–129 day blocks and a month off. Same intermittent-preservation story as older charts. forum
How it may feel
- First night: Spectrum from clear sleepiness/pressure within ~30–60 min, intense vivid dreams, wearable deep-sleep jump, to little/nothing — first-night “wow” and first-night null both common. forum
- Nights 1–3: Dream intensity and morning “actually rested” feel often show before chronic architecture claims; some need 2–3 nights before judging. forum
- Week 1: Checkpoint for onset latency, night awakenings, and whether dreams help or fragment sleep. forum
- Weeks 2–4: Community logs reassess short blocks around this time and debate as-needed versus nightly use. This is a reported review window, not a course instruction. forum
- As-needed pattern: Many reserve for travel, high-stress weeks, or bad-sleep streaks rather than indefinite nightly use. forum
- No change ~1–2 weeks: Forums push recheck of timing (too early/late), sleep hygiene, caffeine/alcohol, source purity, and route — not automatic mega-escalation. forum
- 2025–26 first-night wearable split: r/coachmitch-style 100–120 mcg logs still post “more restorative deep sleep than the last 3 days” screenshots; other 2026 threads say 300 mcg for 2–3 weeks did nothing. Hit-or-miss is still the feel, not a delayed guarantee. forumanecdote
- Inception / lucid-dream feel (still loud): 2025–26 r/Peptides, r/PeptideForum, and r/LucidDreaming logs keep “three layers deep” / too-real dreams at ~250–500 mcg. Some chase it; others quit because REM got loud and sleep fragmented. forum
- Nasal vs SubQ feel: Late-2025 logs still report nasal DSIP as nightmare-heavy, then a switch to SubQ ~100–200 mcg as “slept so well.” Route changes the night more than a second mcg bump for that subset. anecdote
- 400 mcg “jump” nights: April 2026 r/sleep posts describe 300 mcg as meh, then 400 mcg as the first actually-rested morning — followed by talk of titrating toward 500. Not a trial arm. forum
- Daily vs sparse: 2025–26 comments still warn that nightly use can pile grogginess or “it quit,” and that 2–4 nights/week or every-other-day keeps the effect. Tolerance talk is forum lore, not a PK curve. forum
- Delayed / multi-night lore: Older commentary and Pollard & Pomfrett-style notes that a dose can influence the following nights are sometimes repeated — not a validated multi-day PK schedule. trial
- Build-up talk (historical): Schneider-Helmert repeated-administration notes suggested cumulative sleep improvement over several nights in some insomnia protocols. trial
Around the dose
- Clock: Night, close to bed. Daytime DSIP is rare outside failed-sleep experiments. forum
- Sleep hygiene: Dark, cool, no late caffeine — DSIP is not a substitute for those in the threads that keep it. forum
- Night interruptions: Threads emphasize an uninterrupted sleep opportunity and describe 3 a.m. redosing as outside their usual charts, not an established rescue approach. forum
- Wearable night, not a 3 a.m. redose: 2025–26 logs screenshot Oura/Whoop deep-sleep minutes the next morning. A bathroom wake that drops straight back into REM is described; a second pin at 3 a.m. is still not the chart. forum
- Magnesium discussion: Sleep threads compare glycinate or threonate alongside DSIP with reports that malate disturbed sleep around 2–3 a.m. This is disputed combination/timing discussion, not proof that a form will cause or prevent waking. forum
- Nasal vs pin the same clock: Same 30–60 min pre-bed window. People who got nightmares on nasal often retry SubQ at the same clock rather than pushing mcg. forum
- Combination confounding: Some 2026 logs combine DSIP with Xanax or a melatonin gummy and then credit the peptide. Threads debate single-agent observations and warn about combining CNS depressants; these accounts cannot isolate DSIP or establish a safe combination/retry plan. forum
Cycles people discuss
- Short sleep blocks: ~1–4 weeks evening use is the most common structured community run. forum
- Chart template: ~2–4 weeks on / ~2 weeks off appears repeatedly in dosage guides (lower doses sometimes stretched longer on). forum
- Beginner chart example: ~100 mcg nightly × ~2 weeks on / 2 off (illustrative vendor-style, not a trial arm). forum
- Standard chart example: ~200 mcg × ~3–4 weeks on / ~2 off. forum
- Enhanced chart example: ~300 mcg × ~4 weeks on / ~2–3 off. forum
- Stack-length charts: DSIP + Ipamorelin recovery stacks sometimes listed ~4–8 weeks on / ~2–4 weeks off. forum
- As-needed only: Continuous nightly use is often avoided; many never run a formal multi-week block. forum
- Intermittent preservation lore: 2–3 nights/week or 5/2 schedules justified as anti-tolerance — formal desensitization data for DSIP is essentially absent. forum
- Jet-lag short course: ~3–5 nights at destination bedtime discussed anecdotally. forum
- Re-runs: Stress seasons, contest prep sleep wreckage, shift blocks, and travel more than year-long unbroken nightly use. anecdote
- Historical multi-day courses: Insomnia IV work used consecutive-night dosing (e.g., several evenings in a row; some designs ~4–7 nights); pediatric Deltaran CNS notes include ~10-day courses — different products/contexts. trial
- Time off / long-term: Off-blocks discussed inconsistently; no large continuous multi-year safety database; Wikipedia-style summaries note long-term side-effect profile not established. trial
Timing
- Minutes-class secondary estimates: Older secondary/community summaries cite about 7–8 minutes through 30–45 minutes across different model/route discussions. These remain unverified as human in-vivo clearance. FDA repeats an eight-minute shorthand but separately describes animal IV results and human-serum degradation in vitro; none establishes a human subcutaneous half-life. forumanimallab
- Bedtime single dose logic: One evening administration aimed at sleep onset and first-cycle architecture, not all-day plasma levels. forum
- Pre-sleep timing vs half-life: Short half-life is why many argue against dosing 2–3 hours early; 20–60 min pre-bed is the practical compromise band in discussion. forum
- Downstream feel: Cleared peptide vs next-morning recovery after multi-night use; not classic residual benzodiazepine-like sedation for most responders. anecdote
- In-vitro / enzyme stability: Classic characterization reports very low molecular stability with ~15-minute half-life under aminopeptidase-like degradation conditions. lab
- Carrier / precursor theory: Literature suggests complexing with carrier proteins or existence as part of a larger precursor may prolong biological interest beyond free-peptide minutes. trial
- Trigger / cascade framing: Bro and review content both emphasize effects on sleep architecture outlasting circulating peptide — “starts a cascade” rather than steady-state sedation levels. forum
- Delayed sleep pressure (early IV): Schneider-Helmert 1981 morning slow IV (25 nmol/kg): subjects reported immediate sleep pressure; increased sleep and efficiency measures with delayed components after infusion (classically discussed around ~hours-scale sleep effects, not instant KO). trial
- Multi-night residual lore: Occasional claims that a daytime or prior-night dose still improves subsequent nights — weak, non-standard, and not a substitute for sleep hygiene. trial
- Route PK debate: IV (historical) highest controlled exposure; subq modern default but human bioavailability poorly quantified; IN discussed as marketed/community route without established preferential CNS delivery here that still lacks modern PK packages. trial
More on what it is
- Why people talk about it: Top-tier sleep-peptide name on Reddit, biohacking forums, and peptide-clinic content — framed as deeper restorative sleep without classic benzo/Z-drug knockout hangover. forum
- Evidence honesty: Human sleep work is mostly small 1980s European IV studies; FDA describes intranasal commerce separately. Findings are mixed, samples small and modern RCTs limited. Community subcutaneous microgram schedules remain extrapolated discussion, not FDA-labeled dosing. trialforum
- Emideltide is the same nonapeptide, not a second card: Emideltide is the compounding / INN-style name for DSIP. FDA’s July 24, 2026 PCAC voted against listing emideltide free base and acetate on the 503A bulks list (6 yes / 7 no / 1 abstention on both questions) — advisory, not a new compound and not a finished pharmacy green light. trialforum
- What it is: Synthetic nine-amino-acid neuropeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu; ~848–850 Da) first isolated in the mid-1970s from cerebral venous blood of sleeping rabbits by the Schoenenberger–Monnier group; named for inducing delta/slow-wave EEG activity in animal models. trial
- Emideltide / Deltaran names: Emideltide is the compounding/INN-style label for the same nonapeptide sequence; Deltaran is a Russian DSIP-containing pharmaceutical-style preparation discussed in Eastern European CNS work — product identity is not interchangeable with gray-market lyophilized “DSIP” vials. trial
- Mechanism talk (oversimplified in bro content): Promotes or modulates slow-wave/delta sleep architecture, HPA/stress-axis calm before bed, and sometimes GH-during-deep-sleep synergy narratives; receptor/gene story remains incompletely resolved in literature (“still unresolved riddle” reviews). trial
- Endocrine angles in papers: Decreases basal corticotropin / can blunt ACTH release; LH and somatotrophin/somatostatin modulation reported in animal/endocrine work — not a substitute for GH secretagogues. animal
- Not this: Not melatonin, not a benzo/Z-drug, not FDA-approved for insomnia, not a local healing peptide, and not proven first-line vs modern approved sleep drugs on evidence quantity. trial
- Research lens: Treat wearable deep-sleep % jumps and “Inception dreams” logs as discussion data under research-only framing — not proof of clinical efficacy or purity of any vial. forum
Stacks
- Sleep hygiene base first: Dark/cool room, fixed schedule, caffeine cutoffs, alcohol limits — often credited as much as the peptide. forum
- DSIP + Ipamorelin (flagship recovery stack): Common chart ~200 mcg DSIP + ~200 mcg Ipamorelin both ~30 min before bed — DSIP for deep-sleep window, Ipa for GH pulse narrative; chart writers describe separate syringes; compatibility and co-mix stability remain unresolved. forum
- DSIP + CJC-1295 (no DAC) / Mod GRF: Night GH-axis stack alongside or instead of solo Ipa; confounded multi-agent nights. forum
- Full night recovery stack examples (vendor-style): Ipa ~200–300 mcg + CJC no DAC ~100–200 mcg + DSIP ~250–500 mcg (DSIP often not nightly) ± oral MK-677 ~12.5 mg — heavily confounded. forum
- DSIP + Epitalon: Circadian/pineal course layered under sleep nights (Epitalon course schedules differ — not nightly forever). forum
- DSIP + BPC-157 / TB-500: “Heal while you deep-sleep” recovery narrative; different mechanisms, same bedtime session for convenience. forum
- Melatonin microdose pairing: Low-dose melatonin (~0.3–0.5 mg) ~60–90 min pre-bed then DSIP ~30 min — circadian timing vs architecture story; some hate melatonin and drop it. forum
- OTC calm peers: Magnesium, glycine, apigenin, L-theanine compared or combined — additive sedation caution still applies. forum
- vs pure sedatives: Explicit community warning against stacking with benzos, Z-drugs, barbiturates, or heavy alcohol same night due to additive CNS depression risk (unstudied combination). forum
- Stack credit problem: Wearable wins on multi-peptide nights cannot be assigned to DSIP alone. forum
- DSIP + Selank (anxiety-driven insomnia talk): Selank IN ~250–500 mcg earlier evening + DSIP subq nearer bed — dual calm/sleep framing. forum
Access talk
- 2026 community shrug: Peptide-twitter / forum reaction to the no-vote was often “not surprised” / non-responder talk, not a supply panic. RUO vials and clinic nasal/injectable SKUs remain the actual buy talk. forum
- Emideltide = DSIP, not a new peptide: Same nine-amino-acid sequence. July 24, 2026 PCAC voted against adding emideltide free base and acetate to the 503A bulks list (6 yes / 7 no / 1 abstention on both questions). Nominated uses were opioid withdrawal, chronic insomnia, and narcolepsy — not a “sleep optimization” indication. trial
- FDA staff and the panel agreed only here: Agency briefing proposed not listing all seven peptides that week; the committee overruled staff on six and matched staff on emideltide. Naming inconsistency, poor characterization, and a purity profile that “cannot be easily confirmed” were the written concerns — including that the common name can cover more than one molecule. trial
- Nominated SubQ, studied IV: FDA noted no effectiveness study for the nominated subcutaneous route; historical sleep/withdrawal work was intravenous. Community mcg pins are still not that evidence. trial
- Withdrawn nomination, still voted: Wells Pharmacy Network and LDT Health Solutions withdrew peptide nominations in April 2026; FDA said it was evaluating at its discretion. Advisory vote ≠ finished 503A listing ≠ FDA-approved sleep drug. trial
- April 2026 Category 2 off is not a green light: Coming off the do-not-compound bucket is not Category 1, not 503A placement, and not approval. No 503B outsourcing facility had reported compounding emideltide to FDA in the briefing. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Injection site: Redness, irritation, stinging, or burning — some users single out DSIP as hotter than average peptides; rotate sites. forum
- Headache / dizziness: Morning or night headache, lightheadedness, mild dizziness in logs and secondary safety lists. forum
- Hypotension: Older summaries mention blood-pressure drops; FDA describes serious/progressive hypotension in historical IV withdrawal settings. Those settings differ from modern community products. “Start low” lore for people already hypotensive is not an established protection. trialforum
- Morning grogginess: More reported at higher community doses (~300+ mcg); often resolves quickly but can conflict with early obligations. forum
- Paradoxical wired / worse sleep: Minority feel restless, anxious, or sleep worse — stop/reassess rather than escalate is common advice. forum
- Disruptive dreams / nightmares: Intense dreams can fragment sleep or feel “too real”; lucid-dream interest vs night-terror risk is user-specific. anecdote
- Sedative / alcohol combinations: Theoretical additive CNS depression with benzos, Z-drugs, barbiturates, or heavy alcohol — uncharacterized and widely discouraged in community safety notes. forum
- Mood / depression caution: Altered architecture theoretically interacts with mood regulation; clinical depression populations lack modern controlled guidance. forum
- Source quality: Gray-market mislabeling, under/overfill, contamination, and endotoxin risk for injectable material. forum
- Nausea / GI: Transient nausea or stomach discomfort noted in limited human-era summaries. trial
- Route honesty: Subq bioavailability vs historical IV nmol/kg is not established in modern controlled PK; nasal products vary by device and mucosa. trial
- Evidence gaps: Small 1980s samples, mixed clinical significance in some PSG reads, sparse modern RCTs, no established long-term continuous safety. trial
- Not FDA-approved: No approved insomnia indication in the US; compounding/Emideltide regulatory status is jurisdiction- and policy-dependent and can change. trial
- Withdrawal literature is not a DIY protocol: Historical IV inpatient series are not instructions for self-managed detox. trial
- Pregnancy / breastfeeding: No adequate safety data — research-only framing excludes these populations. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.